Research programme: inflammatory disease therapeutics - Ore Pharmaceuticals

Drug Profile

Research programme: inflammatory disease therapeutics - Ore Pharmaceuticals

Alternative Names: ORE 10002

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lundbeck A/S
  • Developer Ore Pharmaceuticals
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA
  • 07 Sep 2010 ORE 10002 is still in preclinical trials for Inflammation in the US
  • 17 Aug 2009 Ore Pharmaceuticals acquires ORE 10002 from Lundbeck A/S
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top